Triple Negative Breast Neoplasms: all 1,163 studies
Page 3 of 12. Open to participants first (447), then studies with results posted, then the rest; newest registration first within each.
- The Optimal Radioimmunotherapy Combinations for Advanced TNBCRecruitingNCT06735131Phase 2
- A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast CancerRecruitingNCT06732323Phase 3
- JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBCNot yet recruitingNCT06731153Phase 2
- A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid TumorsNot yet recruitingNCT06724263Phase 2
- Microbiome Immunotherapy Neoadjuvant AssessmentRecruitingNCT06709651
- Different Methods of Capecitabine in Patients With Non-PCR After Neoadjuvant Therapy for TNBCRecruitingNCT06700382
- A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid TumorsRecruitingNCT06700070Early Phase 1
- De-escalation of Neoadjuvant Chemotherapy Regimens With Immunotherapy Among TNBCRecruitingNCT06692725
- Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and ChemotherapyNot yet recruitingNCT06691594Phase 2
- Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer PatientsRecruitingNCT06690840Phase 2
- A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 ExpressionRecruitingNCT06682793Phase 1/2
- Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)RecruitingNCT06682195Phase 2
- Breast Cancer Evolution During Neoadjuvant Systemic TherapyRecruitingNCT06681064
- Arsenous Acid for Refractory Triple-Negative Breast CancerRecruitingNCT06678048Phase 2
- First in Human Study of TUB-030 in Patients With Advanced Solid TumorsRecruitingNCT06657222Phase 1/2
- Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast CancerRecruitingNCT06649331Phase 2
- Cellular Immune Responses in Triple-negative Breast Cancer - High Throughput Immunogenetic StudiesEnrolling by invitationNCT06646263
- Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast CancerRecruitingNCT06637306Early Phase 1
- All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II TrialRecruitingNCT06636981Phase 2
- Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast CancerRecruitingNCT06635980Phase 2
- Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast CancerRecruitingNCT06631092Phase 1/2
- SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBCRecruitingNCT06627712Phase 3
- A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid TumorsRecruitingNCT06618287Phase 1/2
- Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast CancerRecruitingNCT06606730Phase 3
- A Study With NKT3964 for Adults With Advanced/Metastatic Solid TumorsRecruitingNCT06586957Phase 1
- JK-1201I in Triple Negative Breast Cancer Patients with Brain MetastasesNot yet recruitingNCT06586866Phase 2
- Breast Cancer PSMA PETRecruitingNCT06586047Early Phase 1
- Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast CancerRecruitingNCT06582615Not applicable
- Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal CancersRecruitingNCT06562192Phase 1
- A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor AlphaRecruitingNCT06547840Phase 1
- Study of XB010 in Subjects With Solid TumorsRecruitingNCT06545331Phase 1
- Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical StudyRecruitingNCT06538896Phase 2
- Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical StudyRecruitingNCT06534762Phase 2
- PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBCRecruitingNCT06533384Phase 3
- SMP-3124LP in Adults With Advanced Solid TumorsRecruitingNCT06526819Phase 1/2
- A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast CancerRecruitingNCT06508216Phase 1/2
- Exercise Intervention in Women Diagnosed With Triple-negative Breast Cancer Receiving Oncologic TreatmentNot yet recruitingNCT06497322Not applicable
- High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast CancerRecruitingNCT06492759Phase 2
- A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast CancerRecruitingNCT06492005Phase 2
- OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating LymphocytesRecruitingNCT06476119
- A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast CancerRecruitingNCT06471205Phase 2
- A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsRecruitingNCT06465069Phase 1
- ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast CancerRecruitingNCT06460298Phase 1/2
- This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid TumorsRecruitingNCT06451497Phase 1
- Observational Study on the Sensitivity of Neoadjuvant Immunotherapy in Early Triple-Negative Breast CancerNot yet recruitingNCT06448169
- Evaluation of Recurrence Risk Factors in Locally Advanced Breast Cancer Patients Underwent Neoadjuvant Chemotherapy.RecruitingNCT06441240
- Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant TherapyRecruitingNCT06435351Early Phase 1
- Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast CancerRecruitingNCT06434064Phase 2
- a Single-arm, Single-center, Open Clinical StudyRecruitingNCT06431100
- Access to Genetic Testing in Underserved Patients With CancerRecruitingNCT06422455Not applicable
- Association of Pembrolizumab Infusion Time and Efficacy in Patients With Non-metastatic Triple-negative Breast Cancer (TNBC) Treated With Neoadjuvant Chemotherapy and ImmunotherapyNot yet recruitingNCT06418139
- VISION: Triple Negative Breast Cancer Sample and Clinical Data Acquisition StudyEnrolling by invitationNCT06409221
- Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast CancerNot yet recruitingNCT06407310Phase 2
- QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast CancerNot yet recruitingNCT06404736Phase 2
- SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)RecruitingNCT06401005Phase 2
- A Study of Sofe-M in Participants With Selected Advanced Solid TumorsRecruitingNCT06400472Phase 1
- Deployment and Clinical Evaluation of an AI-powered Digital Oncology Biomarker Tool to guidE Treatment in TNBCNot yet recruitingNCT06396754
- Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)RecruitingNCT06393374Phase 3
- LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast CancerRecruitingNCT06387628Phase 2
- Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant TherapyRecruitingNCT06385990Phase 2
- A Phase I/II Trial of UCB4594 in Participants With Advanced CancerRecruitingNCT06380816Phase 1/2
- Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With PembrolizumabNot yet recruitingNCT06371807Phase 2
- A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.RecruitingNCT06371274Not applicable
- Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast CancerRecruitingNCT06367088Phase 2
- Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast CancerRecruitingNCT06365788Phase 2
- Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKKRecruitingNCT06358573Phase 2
- Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast CancerRecruitingNCT06355037Phase 2
- Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC PatientsRecruitingNCT06353997Phase 2
- 68Ga-FAPI-46 PET/CT for Predicting Histological Response in Triple-negative Breast Cancer (FAP-IT)RecruitingNCT06349512Not applicable
- Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T CellsRecruitingNCT06347068Phase 1
- NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 TrialRecruitingNCT06342037Phase 2
- fREEDOM: REsonance for Early Detection Of Breast Cancer MetastasesRecruitingNCT06328465Not applicable
- Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast CancerRecruitingNCT06324240Phase 1
- Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast CancerRecruitingNCT06318897Phase 2
- 177Lu-anti-PD-L1 sdAb in Metastatic Solid TumorsRecruitingNCT06305962Early Phase 1
- Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast CancerRecruitingNCT06291064Phase 2
- Vabb After Neoadjuvant Therapy to Avoid Surgery-pCR to Avoid Breast SurgeryRecruitingNCT06281210Not applicable
- A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid TumorsRecruitingNCT06270706Phase 1
- Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard ChemotherapyNot yet recruitingNCT06268327Phase 2/3
- LAG3 Expression in Triple Negative Breast CancerRecruitingNCT06259162Not applicable
- Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With PembrolizumabRecruitingNCT06249048Phase 1/2
- A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast CancerRecruitingNCT06246968Phase 1
- PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBCRecruitingNCT06245889Phase 2
- Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain MetastasesRecruitingNCT06238921Phase 1/2
- CtDNA Based MRD Testing for NAC Monitoring in TNBCRecruitingNCT06230185
- Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast CancerNot yet recruitingNCT06229067Phase 2
- Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE)RecruitingNCT06225505Not applicable
- Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer PatientsRecruitingNCT06225284Phase 2
- ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast CancerRecruitingNCT06224673Phase 2
- CTS2190 Phase I /II Clinical Study in PatientsRecruitingNCT06224387Phase 1/2
- Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast CancerRecruitingNCT06220214Early Phase 1
- SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain MetastasesNot yet recruitingNCT06210438Phase 2
- Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast CancerNot yet recruitingNCT06202313Phase 2
- Personalized Vaccine for TNBC ImmunotherapyNot yet recruitingNCT06195618Phase 1
- Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)RecruitingNCT06189209Phase 2
- Prospective Evaluation of AI R&D Tool for Patient Stratification - MoA Evaluation in Triple Negative Breast Cancer (PEAR-MET)RecruitingNCT06182306
- DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEsRecruitingNCT06176261Phase 2
- A Phase 1 of CTX-8371 in Patients With Advanced MalignanciesRecruitingNCT06150664Phase 1
- The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.Not yet recruitingNCT06140576Phase 1/2
- A Study of Tetrathiomolybdate (TM) Plus CapecitabineRecruitingNCT06134375Phase 1/2